[1]张司马康,周春高,施海彬,等.骨骼肌质量指数对TACE治疗肝癌的预测价值[J].介入放射学杂志,2022,31(12):1170-1173.
 ZHANG Simakang,ZHOU Chungao,SHI Haibin,et al.The value of skeletal muscle mass index in predicting the survival time of patients with primary hepatocellular carcinoma receiving transhepatic arterial chemoembolization[J].journal interventional radiology,2022,31(12):1170-1173.
点击复制

骨骼肌质量指数对TACE治疗肝癌的预测价值()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年12
页码:
1170-1173
栏目:
肿瘤介入
出版日期:
2023-01-11

文章信息/Info

Title:
The value of skeletal muscle mass index in predicting the survival time of patients with primary hepatocellular carcinoma receiving transhepatic arterial chemoembolization
作者:
张司马康 周春高 施海彬 刘 圣 张金星 祖庆泉
Author(s):
ZHANG Simakang ZHOU Chungao SHI Haibin LIU Sheng ZHANG Jinxing ZU Qingquan.
Department of Interventional Radiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
关键词:
【关键词】 骨骼肌质量指数 肝细胞癌 肝动脉化疗栓塞术 预后
文献标志码:
A
摘要:
【摘要】 目的 探讨骨骼肌质量指数(SMI)对肝癌患者经肝动脉化疗栓塞术(TACE)治疗后的预测价值。方法 选取2016年11月至2018年12月南京医科大学第一附属医院行TACE治疗的肝癌患者156例。利用X- tile软件计算SMI的最佳截断值,根据最佳截断值将患者分为高SMI组患者106例,低SMI组患者50例。比较两组患者的临床特征和预后,分析肝癌患者TACE治疗后生存期的影响因素。结果 两组患者的年龄、BCLC分期、肿瘤直径、中性粒细胞与淋巴细胞比值(NLR)差异有统计学意义(P<0.05)。术前低SMI水平组的中位生存时间为21.5个月,高SMI水平组的中位生存时间为47.8个月,差异有统计学意义(P<0.01)。多因素分析显示,SMI水平、肿瘤数目、大血管侵犯、AFP、AST、NLR是TACE后患者生存的影响因素。结论 术前SMI水平与TACE治疗肝癌患者的预后密切相关。

参考文献/References:

[1] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7: 1- 28.
[2] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30:367- 388.
[3] Benson AB, D’Angelica MI,Abbott DE,et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19:541- 565.
[4] Cruz- Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48: 16- 31.
[5] Cun J, Xu Y, Li W, et al. Analysis of factors affecting the prognosis of transcatheter arterial chemoembolization for hepatitis B- related hepatocellular carcinoma[J]. J Interv Med, 2021, 4: 66- 70.
[6] Fukushima H, Takemura K, Suzuki H, et al. Impact of sarcopenia as a prognostic biomarker of bladder cancer[J]. Int J Mol Sci, 2018: 19:2999.
[7] Cruz- Jentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393: 2636- 2646.
[8] 向 谦,陈 丽,付 丹,等. 肌肉减少症对接受TACE治疗原发性肝癌患者生存期的影响[J]. 现代消化及介入诊疗, 2021, 26:202- 207.
[9] 丁松明,郑树森. 肌肉减少症对肝细胞肝癌治疗影响的研究进展[J]. 浙江医学, 2022, 44:548- 551.
[10] 刘建营,常 静.肌少症与肝细胞癌的临床研究进展[J]. 中国临床肿瘤, 2020, 47:897- 901.
[11] 杨静仪,勾 熙,毛小荣,等. 肌肉减少症对终末期肝病临床结局和预后影响的研究进展[J]. 肝脏, 2022, 27:245- 247.
[12] 严守美,崔新江,于志军,等. 经肝动脉化疗栓塞联合微波消融治疗巨块型肝癌术前中性粒细胞与淋巴细胞比率监测的临床意义[J]. 介入放射学杂志, 2018, 27:632- 635.
[13] 王富权,斌 柴,周国锋. 中性粒细胞与淋巴细胞比值对TACE联合阿帕替尼治疗进展期肝癌疗效的预测价值[J]. 介入放射学杂志, 2021, 30:244- 248.
[14] Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis[J]. Trends Immunol, 2019, 40:228- 242.
[15] Chew V, Chen J, Lee D, et al. Chemokine- driven lymphocyte infiltration: an early intratumoural event determining long- term survival in resectable hepatocellular carcinoma[J]. Gut, 2012, 61: 427- 438.
[16] Mcgovern J, Dolan RD, Skipworth RJ, et al. Cancer cachexia: a nutritional or a systemic inflammatory syndrome?[J]. Br J Cancer, 2022, 127: 379- 382.
[17] Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age- associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis[J]. Ageing Res Rev, 2017, 35: 200- 221.
[18] Bhanji RA, Moctezuma- Velazquez C, Duarte- Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encepha- lopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12: 377- 386.
[19] Koya S, Kawaguchi T, Hashida R, et al. Effects of in- hospital exercise on sarcopenia in hepatoma patients who underwent tran- scatheter arterial chemoembolization[J]. J Gastroenterol Hepatol, 2019, 34: 580- 588.
[20] Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic- based prognostic factors of colorectal cancers are associated with the state of the local immune reaction[J]. J Clin Oncol, 2011, 29: 610- 618.
[21] Aoyama S, Kim HK, Hirooka R, et al. Distribution of dietary protein intake in daily meals influences skeletal muscle hyper- trophy via the muscle clock[J]. Cell Rep, 2021,36: 109336.

相似文献/References:

[1]叶强.PEIT治疗肝脏恶性肿瘤[J].介入放射学杂志,1998,(01):24.
[2]叶强.肝脏肿瘤的经皮穿刺治疗:技术现状[J].介入放射学杂志,1998,(01):16.
[3]HondaN,Guo Q,Uchida H,等.经皮穿刺灼热生理盐水注射治疗肝癌——一个替代酒精注射的方法[J].介入放射学杂志,1995,(02):121.
[4]刘鹏芝,韩金红,赵凤珍,等.肝癌介入治疗中导管和导丝系列的清洗和消毒[J].介入放射学杂志,1996,(01):50.
[5]罗正益,李兴跃.肝脏疾病的血管造影诊断[J].介入放射学杂志,1996,(01):26.
[6]罗正益,曾炳生,郝春志,等.小肝癌CT和血管造影诊断——自内向外顺序染色征象的意义[J].介入放射学杂志,1996,(01):30.
[7]张大海,顾伟中,叶强.肝细胞癌的非手术治疗[J].介入放射学杂志,2000,(02):122.
[8]张璐西,施海彬,刘 圣,等.ACE联合索拉非尼治疗BCLC C期肝细胞癌20例疗效分析[J].介入放射学杂志,2014,(11):954.
 ZHANG Lu xi,SHI Hai bin,LIU Sheng,et al.Transarterial chemoembolization combined with sorafenib for hepatocellular carcinoma in BCLC C stage: clinical analysis of 20 cases[J].journal interventional radiology,2014,(12):954.
[9]赵 丹,梁 斌,王 勇,等.肝癌化疗栓塞后溶瘤综合征1例 [J].介入放射学杂志,2018,27(05):461.
 ZHAO Dan,LIANG Bin,WANG Yong,et al.Tumor lysis syndrome after transcatheter arterial chemoembolization: report of one case[J].journal interventional radiology,2018,27(12):461.
[10]张 雯,李 说,颜志平,等.植入性门静脉主干癌栓兔模型建立及评估[J].介入放射学杂志,2015,(09):801.
 ZHANG Wen,LI Shuo,YAN Zhi- ping,et al.Implanted main portal venous tumor thrombus model in experimental rabbits: its establishment and evaluation[J].journal interventional radiology,2015,(12):801.

备注/Memo

备注/Memo:
(收稿日期:2022- 08- 31)
(本文编辑:新 宇)
更新日期/Last Update: 2023-01-11